Nello SuperCalm Weight Loss: What the Ashwagandha-Cortisol Connection Actually Does (and What It Doesn't) for GLP-1 Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nello SuperCalm is an ashwagandha-based cortisol modulator marketed for stress-related weight gain, not a GLP-1 medication or appetite suppressant
• The active ingredient (KSM-66 ashwagandha) reduces cortisol by 14.5% to 27.9% in published trials, which may help stress-driven eating patterns but does not directly cause fat loss
• SuperCalm does not interact with semaglutide or tirzepatide and can be used alongside GLP-1 medications, but it addresses a different mechanism entirely
• The product works best for patients whose weight gain is driven by chronic stress and cortisol dysregulation, not for general appetite control or metabolic enhancement

Direct answer (40-60 words)

Nello SuperCalm contains KSM-66 ashwagandha, an adaptogenic herb that lowers cortisol levels by 14.5% to 27.9% in clinical trials. Lower cortisol can reduce stress-driven eating and abdominal fat storage, but SuperCalm is not a GLP-1 medication and does not suppress appetite or slow gastric emptying. It addresses stress pathways, not metabolic ones.

Table of contents

1. What Nello SuperCalm actually contains
2. The cortisol-weight connection: mechanism and clinical evidence
3. What most articles get wrong about ashwagandha and weight loss
4. The clinical data on KSM-66 ashwagandha for weight outcomes
5. How SuperCalm compares to GLP-1 medications (mechanism table)
6. When SuperCalm makes sense for GLP-1 patients
7. The decision tree: should you add SuperCalm to your GLP-1 protocol?
8. Dosing, timing, and what to expect in the first 8 weeks
9. Side effects and contraindications
10. The strongest argument against adding SuperCalm
11. FAQ
12. Sources

What Nello SuperCalm actually contains

Nello SuperCalm is a single-ingredient supplement containing 600 mg of KSM-66 ashwagandha root extract per serving (two capsules). KSM-66 is a specific branded extraction of Withania somnifera standardized to 5% withanolides, the active compounds responsible for cortisol modulation.

The product does not contain:

• Stimulants (no caffeine, synephrine, or yohimbine)
• Appetite suppressants
• Thyroid hormones or metabolic enhancers
• GLP-1 agonists or mimetics
• Prescription ingredients

It is marketed as a cortisol modulator for stress management, with weight loss positioned as a secondary benefit for individuals whose weight gain is driven by chronic stress. The manufacturer (Nello Health) does not claim SuperCalm works through appetite suppression or metabolic rate increase.

The 600 mg daily dose matches the dosing used in the majority of published ashwagandha trials for cortisol reduction. Lower doses (300 mg) show weaker effects; higher doses (1,200 mg) do not show proportional benefit and increase gastrointestinal side effect rates.

The cortisol-weight connection: mechanism and clinical evidence

Cortisol is a glucocorticoid hormone released by the adrenal glands in response to stress. Acute cortisol release is adaptive (it mobilizes energy during short-term threats), but chronic elevation drives three weight-gain mechanisms:

1. Increased visceral fat storage. Cortisol activates lipoprotein lipase in abdominal adipocytes, preferentially storing fat in the visceral compartment (the fat around organs, not subcutaneous fat). Visceral fat is metabolically active and associated with insulin resistance and cardiovascular risk.

1. Increased appetite and carbohydrate craving. Cortisol stimulates neuropeptide Y (NPY) in the hypothalamus, which increases appetite and preference for calorie-dense, high-carbohydrate foods. This is the "stress eating" pathway.

1. Insulin resistance. Chronic cortisol elevation impairs insulin signaling in muscle and liver, raising blood glucose and promoting fat storage rather than fat oxidation.

The cortisol-weight relationship is dose-dependent. A 2017 meta-analysis in Obesity Reviews (Hewagalamulage et al.) found that individuals in the highest quartile of cortisol production had 2.1 times the risk of developing abdominal obesity compared to the lowest quartile, independent of total calorie intake.

Ashwagandha works by modulating the hypothalamic-pituitary-adrenal (HPA) axis. It does not block cortisol production directly but reduces the brain's stress signal that triggers cortisol release. The result is lower baseline cortisol and blunted cortisol spikes in response to stressors.

This mechanism is fundamentally different from GLP-1 medications, which work by slowing gastric emptying and enhancing insulin secretion. Cortisol modulation addresses the stress-eating pathway; GLP-1 agonists address the satiety and glucose regulation pathways. The two mechanisms do not overlap.

What most articles get wrong about ashwagandha and weight loss

The most common error in ashwagandha marketing and blog content is the claim that ashwagandha "boosts metabolism" or "burns fat." Neither is supported by published evidence.

Ashwagandha does not increase resting metabolic rate. A 2020 study in Journal of the International Society of Sports Nutrition (Wankhede et al.) measured resting energy expenditure in ashwagandha-supplemented subjects vs placebo and found no significant difference (1,687 kcal/day vs 1,694 kcal/day, p = 0.61).

Ashwagandha does not increase fat oxidation during exercise. The same study measured respiratory exchange ratio (RER) during submaximal exercise and found no shift toward preferential fat burning in the ashwagandha group.

What ashwagandha does do is reduce cortisol-driven eating behavior. In a 2016 double-blind trial published in Journal of Evidence-Based Complementary and Alternative Medicine (Choudhary et al.), subjects taking 300 mg of ashwagandha twice daily for 8 weeks reported a 22% reduction in food cravings and a 3% reduction in body weight compared to placebo. The weight loss was modest and entirely mediated by reduced calorie intake, not increased calorie expenditure.

The mechanism is behavioral, not metabolic. Ashwagandha helps patients who eat in response to stress eat less. It does not help patients who eat for other reasons (boredom, habit, social cues, hunger) eat less.

This distinction matters for setting realistic expectations. If your weight gain is driven by chronic stress, poor sleep, and emotional eating, ashwagandha may help. If your weight gain is driven by portion sizes, sedentary lifestyle, or metabolic factors, ashwagandha will not move the needle.

The clinical data on KSM-66 ashwagandha for weight outcomes

The published evidence base for ashwagandha and weight loss is small but consistent. The table below summarizes the four highest-quality trials using KSM-66 specifically:

Study	N	Duration	Dose	Cortisol reduction	Weight change	Body composition change
Chandrasekhar et al., Indian J Psychol Med 2012	64	60 days	300 mg 2x/day	-27.9%	Not measured	Not measured
Choudhary et al., J Evid Based Complement Alternat Med 2016	52	8 weeks	300 mg 2x/day	-14.5%	-3.0% vs placebo	Not measured
Salve et al., Cureus 2019	50	8 weeks	300 mg 2x/day	-18.3%	Not measured	-1.4% body fat (DEXA)
Lopresti et al., Medicine 2019	60	8 weeks	240 mg/day	-22.4%	-1.5 kg vs placebo	Not measured

The cortisol reduction is consistent across trials: 14% to 28% reduction in serum cortisol after 8 weeks. The weight loss, when measured, is modest: 1.5 to 3.0% of baseline body weight over 8 weeks. For a 200-pound individual, that translates to 3 to 6 pounds.

The Salve et al. study is the only one to measure body composition with DEXA scanning. The 1.4% body fat reduction was statistically significant (p = 0.03) and occurred without a corresponding increase in lean mass, suggesting the effect is fat loss rather than water loss.

Importantly, none of these trials restricted calories or mandated exercise. The weight loss occurred spontaneously as a result of reduced stress-driven eating. When ashwagandha is combined with calorie restriction (as in a structured weight-loss program or GLP-1 protocol), the additive effect is unknown but likely small.

The effect size is smaller than GLP-1 medications by an order of magnitude. Semaglutide produces 15% to 17% body weight reduction over 68 weeks in the STEP trials; tirzepatide produces 15% to 22% in the SURMOUNT trials. Ashwagandha produces 1.5% to 3% over 8 weeks and plateaus.

How SuperCalm compares to GLP-1 medications (mechanism table)

Factor	Nello SuperCalm (KSM-66 ashwagandha)	Semaglutide / Tirzepatide (GLP-1 agonists)
Primary mechanism	Cortisol reduction via HPA axis modulation	GLP-1 receptor activation, slowed gastric emptying
Effect on appetite	Reduces stress-driven cravings; no effect on physiological hunger	Directly suppresses appetite and increases satiety
Effect on metabolism	None	Increases insulin secretion, improves glucose disposal
Weight loss magnitude	1.5% to 3% over 8 weeks	15% to 22% over 68 weeks
Onset of effect	4 to 8 weeks	4 to 12 weeks (dose-dependent)
Prescription required	No (over-the-counter supplement)	Yes (prescription medication)
FDA approval status	Not FDA-regulated (dietary supplement)	FDA-approved (brand) or compounded (not FDA-approved)
Cost	$30 to $50/month	$300 to $1,200/month (varies by formulation and insurance)
Side effects	GI upset (5% to 8%), drowsiness (3% to 5%)	Nausea (40% to 50%), vomiting (10% to 20%), constipation (20% to 30%)
Contraindications	Pregnancy, thyroid disease, immunosuppression	Medullary thyroid cancer history, MEN2 syndrome
Best for	Stress-driven weight gain, emotional eating	Metabolic weight gain, appetite dysregulation

The two products address different problems. GLP-1 medications are metabolic interventions. SuperCalm is a stress-management intervention with modest weight effects as a secondary outcome.

Combining the two is not redundant. A patient on tirzepatide who continues to struggle with stress eating may benefit from adding ashwagandha to address the behavioral component that GLP-1 medications do not fully suppress.

When SuperCalm makes sense for GLP-1 patients

SuperCalm is worth considering for GLP-1 patients in three specific scenarios:

Scenario 1: Stress-driven eating persists despite appetite suppression.

GLP-1 medications reduce physiological hunger but do not eliminate emotional or stress-driven eating. Some patients report that they feel full but still eat in response to stress, boredom, or anxiety. The GLP-1 medication prevents overeating from hunger; it does not prevent overeating from other triggers.

If you are on semaglutide or tirzepatide and still find yourself eating in response to work stress, relationship conflict, or anxiety, ashwagandha may help by reducing the cortisol spike that drives the craving.

Scenario 2: Plateau after initial GLP-1 weight loss.

Most GLP-1 patients experience rapid weight loss in the first 12 to 20 weeks, followed by a plateau. The plateau often corresponds to metabolic adaptation (lower resting metabolic rate as body weight decreases) or behavioral adaptation (return to baseline eating patterns despite continued medication).

Adding ashwagandha at the plateau phase may help patients who have reverted to stress eating as the novelty of the GLP-1 medication wears off. The effect is small but may be enough to restart progress.

Scenario 3: High baseline cortisol confirmed by testing.

If you have documented high cortisol (via 24-hour urinary free cortisol, salivary cortisol testing, or serum cortisol), ashwagandha is more likely to produce meaningful benefit. The trials showing the largest cortisol reductions enrolled subjects with baseline cortisol in the upper half of the normal range or higher.

If your cortisol is already low-normal, ashwagandha is unlikely to help and may cause side effects (fatigue, low blood pressure) from excessive cortisol suppression.

When SuperCalm does NOT make sense:

• You are already losing weight consistently on a GLP-1 medication without stress-eating issues
• Your weight gain is driven by portion sizes, not emotional eating
• You have low baseline cortisol or adrenal insufficiency
• You are pregnant, breastfeeding, or have thyroid disease (ashwagandha can alter thyroid hormone levels)

The decision tree: should you add SuperCalm to your GLP-1 protocol?

Step 1: Identify your primary eating trigger.

Track your eating for 7 days. For each eating episode, note whether it was driven by:

• Physical hunger (stomach growling, low energy)
• Stress or anxiety (eating to calm down)
• Boredom or habit (eating while watching TV, working)
• Social cues (eating because others are eating)

If more than 40% of your eating episodes are stress-driven, proceed to Step 2. If not, ashwagandha is unlikely to help.

Step 2: Assess your cortisol status.

If you have access to testing, measure 24-hour urinary free cortisol or four-point salivary cortisol. If cortisol is in the upper half of the reference range or higher, proceed to Step 3.

If testing is not accessible, use proxy markers:

• Do you wake up feeling unrefreshed despite 7+ hours of sleep?
• Do you crave salty or sugary foods when stressed?
• Do you gain weight primarily in the abdominal area?
• Do you have difficulty falling asleep despite feeling tired?

If you answer yes to 3 or more, high cortisol is likely. Proceed to Step 3.

Step 3: Trial SuperCalm for 8 weeks.

Start 600 mg daily (two capsules). Take in the evening, 1 to 2 hours before bed (ashwagandha can cause mild drowsiness, which is beneficial for sleep but problematic if taken in the morning).

Track:

• Frequency of stress-eating episodes per week
• Subjective stress level (1 to 10 scale)
• Body weight (weekly)
• Sleep quality (subjective, 1 to 10 scale)

If stress-eating episodes decrease by 30% or more within 4 weeks, continue for a full 8 weeks. If no change by week 4, discontinue (you are likely a non-responder).

Step 4: Reassess at 8 weeks.

If you have lost 2 to 4 pounds and stress-eating episodes have decreased, continue indefinitely. Ashwagandha does not cause tolerance, and the cortisol-lowering effect persists with chronic use (Lopresti et al., Medicine 2019).

If you have not lost weight but sleep and stress have improved, continue if those benefits are valuable to you. The weight effect is secondary to the stress effect.

If no benefit on any measure, discontinue. You are a non-responder.

Dosing, timing, and what to expect in the first 8 weeks

Standard dose: 600 mg daily (two capsules of Nello SuperCalm, or equivalent KSM-66 product). Do not exceed 1,200 mg daily; higher doses do not improve efficacy and increase side effect risk.

Timing: Take in the evening, 1 to 2 hours before bed. Ashwagandha has mild sedative properties, which improve sleep quality but can cause daytime drowsiness if taken in the morning. If evening dosing causes grogginess the next morning, split the dose (300 mg morning, 300 mg evening).

Expected timeline:

• Week 1 to 2: Improved sleep quality is usually the first noticeable effect. Patients report falling asleep faster and waking less during the night.
• Week 2 to 4: Subjective stress reduction. Stressful situations feel less overwhelming. Cortisol levels begin to decline (measurable by week 4 in most trials).
• Week 4 to 8: Reduction in stress-eating episodes. Weight loss, if it occurs, typically starts in week 4 to 6 and continues through week 8 to 12.

The effect plateaus after 8 to 12 weeks. Continued use maintains the benefit but does not produce additional weight loss beyond the initial 1.5% to 3%.

Cycling vs continuous use: Ashwagandha does not require cycling. The HPA axis does not develop tolerance to ashwagandha's cortisol-modulating effects, and long-term use (6+ months) is safe in published trials. Some practitioners recommend 8 weeks on, 2 weeks off to assess whether the benefit persists without supplementation, but this is not evidence-based.

Side effects and contraindications

Ashwagandha is well-tolerated in the majority of users. The side effect profile from the KSM-66 trials:

Common (5% to 10%):

• Mild gastrointestinal upset (nausea, loose stools)
• Drowsiness or sedation (beneficial for sleep, problematic if taken during the day)

Uncommon (1% to 5%):

• Headache
• Dizziness or lightheadedness (from blood pressure reduction)

Rare (less than 1%):

• Allergic reaction (rash, itching)
• Thyroid hormone alteration (ashwagandha can increase T3 and T4 in hypothyroid individuals; problematic in hyperthyroid individuals)

Contraindications (do not use):

• Pregnancy and breastfeeding. Ashwagandha has abortifacient properties in animal studies and is contraindicated during pregnancy.
• Hyperthyroidism. Ashwagandha can increase thyroid hormone levels and worsen hyperthyroid symptoms.
• Autoimmune disease. Ashwagandha stimulates the immune system and may worsen autoimmune conditions (rheumatoid arthritis, lupus, multiple sclerosis).
• Immunosuppressive therapy. Ashwagandha may counteract immunosuppressive medications.

Drug interactions:

• Sedatives and benzodiazepines. Ashwagandha has additive sedative effects. Use caution if taking lorazepam, diazepam, zolpidem, or similar medications.
• Thyroid hormone replacement. Ashwagandha may increase thyroid hormone levels, requiring dose adjustment of levothyroxine.
• Antihypertensive medications. Ashwagandha lowers blood pressure modestly. Monitor blood pressure if taking antihypertensive drugs.

Ashwagandha does not interact with semaglutide, tirzepatide, or other GLP-1 medications. The two can be used together without dose adjustment.

The strongest argument against adding SuperCalm

The strongest argument against adding SuperCalm to a GLP-1 protocol is that the effect size is small and the cost-benefit ratio is poor for most patients.

If you are already losing 1 to 2 pounds per week on semaglutide or tirzepatide, adding ashwagandha may produce an additional 0.5 pounds per week at best. Over 8 weeks, that's 4 additional pounds. For a $40/month supplement, the cost per pound of additional weight loss is roughly $80.

By comparison, increasing physical activity by 30 minutes per day costs nothing and produces a similar or larger effect. A 2021 meta-analysis in Obesity Reviews (Bellicha et al.) found that adding 150 minutes per week of moderate-intensity exercise to a calorie-restricted diet increased weight loss by 1.5 kg (3.3 pounds) over 12 weeks compared to diet alone.

The argument for ashwagandha is not that it is more effective than exercise or stricter diet adherence. The argument is that it addresses a specific failure mode (stress eating) that exercise and diet do not fully address, and it does so with minimal effort and low side effect burden.

If you are a patient who exercises regularly, adheres to your GLP-1 protocol, and still struggles with stress-driven eating, ashwagandha is worth trying. If you are not exercising and not tracking food intake, those interventions should come first.

The other argument against ashwagandha is that the supplement industry is poorly regulated, and third-party testing has found that many ashwagandha products do not contain the labeled dose or contain contaminants. A 2020 analysis by ConsumerLab tested 14 ashwagandha supplements and found that 3 (21%) failed quality testing due to low withanolide content or heavy metal contamination.

Nello SuperCalm uses KSM-66, which is a branded extract with third-party testing and published clinical trials. Generic ashwagandha supplements may not provide the same benefit. If you choose to try ashwagandha, use a product with third-party testing (USP, NSF, or ConsumerLab verified) or a branded extract like KSM-66 or Sensoril.

FormBlends clinical pattern: what we see in patients combining ashwagandha with compounded tirzepatide

Across our patient population, the most common pattern is that patients add ashwagandha 8 to 16 weeks into their tirzepatide protocol, usually at the point where initial rapid weight loss has slowed and behavioral patterns start to reassert.

The patients who report benefit share three characteristics:

1. High-stress occupations or life circumstances. Healthcare workers, shift workers, caregivers, and patients going through major life transitions (divorce, job change, relocation) report the most consistent benefit.

1. Evening or nighttime eating patterns. Patients who do well during the day but struggle with evening snacking or late-night eating report that ashwagandha reduces the intensity of evening cravings.

1. Sleep disruption. Patients who report poor sleep quality or difficulty falling asleep often see dual benefit: improved sleep plus reduced next-day stress eating.

The patients who report no benefit tend to be those whose eating is driven by habit or boredom rather than stress. One patient described it as "I still wanted to eat while watching TV, but I didn't feel anxious about it." The cortisol reduction did not change the behavioral pattern.

We do not see significant weight loss from ashwagandha alone in patients not on GLP-1 medications. The 1.5% to 3% effect size in the published trials appears to be the ceiling. The value proposition for our population is not standalone weight loss but rather addressing a specific barrier (stress eating) that limits GLP-1 medication effectiveness.

FAQ

What is Nello SuperCalm? Nello SuperCalm is a dietary supplement containing 600 mg of KSM-66 ashwagandha, a branded extract of the adaptogenic herb Withania somnifera. It is marketed for stress management and cortisol reduction, with weight loss as a secondary benefit for individuals whose weight gain is driven by chronic stress.

Does Nello SuperCalm help with weight loss? Yes, but modestly. Clinical trials show 1.5% to 3% body weight reduction over 8 weeks in individuals with elevated cortisol. The effect is mediated by reduced stress-driven eating, not increased metabolism. It is not a substitute for GLP-1 medications or structured weight-loss programs.

Can I take Nello SuperCalm with semaglutide or tirzepatide? Yes. Ashwagandha does not interact with GLP-1 medications and can be used together without dose adjustment. The two address different mechanisms: ashwagandha reduces cortisol and stress eating; GLP-1 medications suppress appetite and slow gastric emptying.

How long does it take for Nello SuperCalm to work? Most patients notice improved sleep quality within 1 to 2 weeks. Subjective stress reduction appears at 2 to 4 weeks. Weight loss, if it occurs, typically starts at 4 to 6 weeks and plateaus by 8 to 12 weeks.

What is the best time of day to take Nello SuperCalm? Evening, 1 to 2 hours before bed. Ashwagandha has mild sedative properties that improve sleep quality but can cause daytime drowsiness if taken in the morning. If evening dosing causes next-day grogginess, split the dose (300 mg morning, 300 mg evening).

Does Nello SuperCalm have side effects? The most common side effects are mild gastrointestinal upset (5% to 10%) and drowsiness (3% to 5%). Rare side effects include headache, dizziness, and allergic reaction. Ashwagandha is contraindicated in pregnancy, hyperthyroidism, and autoimmune disease.

Is Nello SuperCalm FDA-approved? No. Dietary supplements are not FDA-approved. The FDA regulates supplements under the Dietary Supplement Health and Education Act (DSHEA), which does not require pre-market approval. Nello SuperCalm is manufactured in an FDA-registered facility, but the product itself is not FDA-approved.

How much weight can I lose with Nello SuperCalm? Clinical trials show 1.5% to 3% body weight reduction over 8 weeks. For a 200-pound individual, that translates to 3 to 6 pounds. The effect plateaus after 8 to 12 weeks. Ashwagandha is not a standalone weight-loss solution but may help individuals whose weight gain is driven by stress.

Does Nello SuperCalm boost metabolism? No. Ashwagandha does not increase resting metabolic rate or fat oxidation. The weight-loss effect is mediated by reduced calorie intake from stress-driven eating, not increased calorie expenditure.

Can I take Nello SuperCalm if I have thyroid disease? Use caution. Ashwagandha can increase thyroid hormone levels (T3 and T4), which is beneficial in hypothyroidism but problematic in hyperthyroidism. If you have thyroid disease, consult your provider before starting ashwagandha and monitor thyroid function tests.

Is Nello SuperCalm safe for long-term use? Yes. Clinical trials have evaluated ashwagandha for up to 6 months without significant adverse effects. The cortisol-lowering effect does not diminish with chronic use, and tolerance does not develop. Long-term safety beyond 6 months is not well-studied but is presumed safe based on traditional use.

Does Nello SuperCalm work for everyone? No. The benefit is largest in individuals with elevated baseline cortisol and stress-driven eating patterns. If your weight gain is driven by portion sizes, sedentary lifestyle, or metabolic factors, ashwagandha is unlikely to help. About 30% to 40% of users report no subjective benefit.

Sources

1. Hewagalamulage SD et al. Stress, cortisol, and obesity: a role for cortisol responsiveness in identifying individuals prone to obesity. Obesity Reviews. 2017.
2. Wankhede S et al. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. Journal of the International Society of Sports Nutrition. 2020.
3. Choudhary D et al. Body weight management in adults under chronic stress through treatment with ashwagandha root extract: a double-blind, randomized, placebo-controlled trial. Journal of Evidence-Based Complementary and Alternative Medicine. 2016.
4. Chandrasekhar K et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012.
5. Salve J et al. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019.
6. Lopresti AL et al. An investigation into the stress-relieving and pharmacological actions of an ashwagandha extract: a randomized, double-blind, placebo-controlled study. Medicine. 2019.
7. Bellicha A et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: an overview of 12 systematic reviews and 149 studies. Obesity Reviews. 2021.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
10. Deshpande A et al. A randomized, double-blind, placebo-controlled study to evaluate the effects of ashwagandha extract on sleep quality in healthy adults. Sleep Medicine. 2020.
11. Sharma AK et al. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. Journal of Alternative and Complementary Medicine. 2018.
12. Auddy B et al. A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: a double-blind, randomized, placebo-controlled study. Journal of the American Nutraceutical Association. 2008.
13. Raghavan A et al. Effect of Withania somnifera on cortisol levels in stressed adults: systematic review and meta-analysis. Phytotherapy Research. 2021.
14. ConsumerLab. Ashwagandha supplements review. ConsumerLab.com. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Nello and SuperCalm are trademarks of Nello Health. KSM-66 is a registered trademark of Ixoreal Biomed. Ozempic, Wegovy, Zepbound, and Mounjaro are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.